Equities

Surmodics Inc

Surmodics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)39.19
  • Today's Change0.02 / 0.05%
  • Shares traded2.00
  • 1 Year change+15.64%
  • Beta1.2251
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Surmodics Inc's revenues fell -4.91% from 132.58m to 126.08m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 1.54m to a larger loss of 11.54m.
Gross margin73.81%
Net profit margin-9.15%
Operating margin-4.48%
Return on assets-6.34%
Return on equity-9.67%
Return on investment-7.22%
More ▼

Cash flow in USDView more

In 2024, cash reserves at Surmodics Inc fell by 5.30m. However, the company earned 248.00k from its operations for a Cash Flow Margin of 0.20%. In addition the company used 2.94m on investing activities and also paid 2.95m in financing cash flows.
Cash flow per share-0.2011
Price/Cash flow per share--
Book value per share8.30
Tangible book value per share3.54
More ▼

Balance sheet in USDView more

Surmodics Inc has a Debt to Total Capital ratio of 19.91%, a lower figure than the previous year's 24.52%.
Current ratio3.96
Quick ratio3.22
Total debt/total equity0.2486
Total debt/total capital0.1991
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -644.97%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-613.97
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.